Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

NCT00045110 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

136

Enrollment

NIH

Sponsor class

Conditions

Adult Anaplastic Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Adult Grade I Meningioma
Adult Grade II Meningioma
Adult Grade III Meningioma
Recurrent Adult Brain Tumor

Interventions

DRUG: erlotinib hydrochloride
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)